SOUTH SAN FRANCISCO, Calif., March 2, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGND), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that, on March 1, 2011, the Company received a determination from the NASDAQ Listing Qualifications Panel (the “Panel”) enabling its Common Stock to trade on The NASDAQ Capital Market. The Company will have until June 13, 2011 to demonstrate compliance with the minimum $1.00 per share closing bid price requirement (“Bid Price”) and all continued listing standards of The NASDAQ Capital Market.
